# Paul Biondi

> Paul Biondi is a Series B investor at Bristol-Myers Squibb backing Medical. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb)
- Location: New York, United States
- Total investments: 1
- Last investment: Jan 2018
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/paul-biondi-422522

Paul Biondi is a Series B investor at Bristol-Myers Squibb in New York focused on Medical and Genetics. Paul Biondi is the executive partner at Flagship Pioneering.Paul Biondi attended Northwestern University - Kellogg School of Management.

## Contacts

5 contacts available for Paul Biondi: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/paul-biondi?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Genetics | 1 | 100% |
| Analytics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Bioinformatics | 1 | 100% |

6 industries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Personal Genome Diagnostics | Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basisof human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States. | $75M | Series B | Jan 04, 2018 | http://personalgenome.com |

1 of 1 investments shown.

## Co-investors
- Co-win Healthcare Fund — VC Fund, 1 deal together
- [3B Future Health Fund](https://shizune.co/investors/profile/helsinn-investment-fund) — VC Fund, 1 deal together
- Inova Strategic Investments — VC Fund, 1 deal together
- [Maryland Venture Fund](https://shizune.co/investors/profile/maryland-venture-fund) — VC Fund, 1 deal together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 1 deal together
- [Windham Venture Partners](https://shizune.co/investors/profile/windham-venture-partners) — VC Fund, 1 deal together

## About Bristol-Myers Squibb

VC Fund · New York, United States

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products.

5 contacts available at Bristol-Myers Squibb.

| Name | Title | Profile |
| --- | --- | --- |
| John damonti | Foundation President | https://shizune.co/investors/profile/john-damonti |
| Chris Boerner | Executive Vice President, Chief Commercialization Officer | https://shizune.co/investors/profile/chris-boerner |
| Debra Boyko-DeBrito | Director Content Management Solutions | https://shizune.co/investors/profile/debra-boyko-debrito |
| Donald J. Hayden, Jr. | President | https://shizune.co/investors/profile/donald-j-hayden-jr |
| Doug Bassett | SVP Informatics & Predictive Sciences | https://shizune.co/investors/profile/doug-bassett |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Paul Biondi invest in?

Paul Biondi invests primarily in Medical, Genetics and Analytics startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Paul Biondi?

Public channels for Paul Biondi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Paul Biondi last invest?

The most recent investment recorded for Paul Biondi closed in Jan 2018. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co